Ever since the COVID-19 pandemic hit the world, researchers have been giving every possible information to help in better treatment. According to new research, people over age 65 at the highest risk for severe COVID-19 have often been the least likely to receive monoclonal antibodies (mAbs). -- a highly effective treatment for the disease -- both across and within US states.

The research was co-authored by researchers from Harvard T.H. Chan School of Public Health. The analysis was published online in JAMA. "Monoclonal antibodies should first go to patients at the highest risk of death from COVID-19, but the opposite happened -- the healthiest patients were the most likely to get treatment. Unfortunately, our federal and state system for distributing these drugs has failed our most vulnerable patients," said Michael Barnett, assistant professor of health policy and management at Harvard Chan School and lead author of the study.

Monoclonal antibodies are very effective at treating mild to moderate COVID-19 infection among non-hospitalised patients. But during the pandemic, mAbs have been in short supply. Federal guidelines prioritise patients at higher risk of being hospitalised or dying from COVID-19, including older people and those with chronic conditions.

The researchers wanted to learn how the limited supply of mAb therapy was allocated to patients at the highest risk for severe disease. They looked at data from more than 1.9 million Medicare beneficiaries who had been diagnosed with COVID-19 between November 2020 and August 2021, and compared rates of receiving mAbs by age, sex, race and ethnicity, region, and number of chronic conditions.

Speculating as to why mAb therapy often failed to reach the highest-risk COVID-19 patients, the researchers said it's possible that higher-risk patients may have had difficulty navigating the multiple steps needed to receive mAbs, from receiving a timely diagnosis to referral and scheduling an infusion within 10 days.

As for differences among states, they suggested that mAb supply may have been low or less used by clinicians in some regions of the US. "We need new approaches to prevent these inequities from happening again with newer treatments on the horizon," said Barnett.